MoneyWorks4Me

AstraZeneca Pharma India informs about updates

28 Mar 2025 Evaluate

AstraZeneca Pharma India has informed that the company will be discontinuing with the manufacturing and marketing of the product Prolonged release Isosorbide-5-mononitrate Tablets BP 30 mg and 60 mg (Imdur) from April 1, 2025. Imdur is currently being indicated for Prophylactic treatment of angina pectoris.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1756.90
Dr. Reddys Labs. 1195.10
Cipla 1303.30
Lupin 1960.00
Zydus Lifesciences 1115.10
View more..